Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Note on the offering

<< Previous

Bullboard Posts

Next >>

Post by SABBOBCATon Jan 14, 2021 3:01pm

223 Views

Post# 32298719

Note on the offering

So I was looking through SEDAR at the offering documents and a couple interesting things popped up. 1) Unfortunately for our friends south of the border, the warrants aren't registered with the SEC so you likely won't be able to buy/trade them. This will not make institutions happy. This info is in the prospectus. 2) the warrants may not list. There is an "other" document posted on the 13 that use a draft term sheet that shows this wording was removed. 3) WHO THE HELL POSTS A DRAFT TERM SHEET TO SEDAR??? What a joke of a company and a bank (on Mackie's part.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario